English 
Español
Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc región.
Related Articles
-
UDIBI
October 6, 2021 Increased survival in puppies affected by Canine Parvovirus type II using an immunomodulator as a therapeutic...
-
UDIBI
Published : March 2021 Poor survival in COVID-19 associated with Lymphopenia and Higher Neutrophile-Lymphocyte ratio More information
-
UDIBI
Mycobacterium tuberculosis Catalase Inhibits the Formation of Mast Cell Extracellular Traps. SHOW MORE
-
-
-
UDIBI
Validation of a cell proliferation assay to assess the potency of a Dialyzable Leucocyte Extract intended for batch release....
-
UDIBI
Identity Profiling of Complex Mixtures of Peptide Products by Structural and Mass Mobility Orthogonal Analysis. SHOW MORE
-
UDIBI
Sequencing Analysis and Identification of the Primary Peptide Component of the Dialyzable Leukocyte Extract “Transferon Oral”: The Starting Point...
